MAPT and Alzheimer disease: Biomarkers are crucial to identify this stage, and they also have a role in enriching preventive clinical trials with individuals at higher risk of progression. Core AD biomarkers include amyloid-beta (Aβ) and tau proteins measured in CSF or PET imaging.